Omics-Based Clinical Trials Global Market Report 2025

Description

Omics-based clinical trials are studies that utilize omics technologies such as genomics, proteomics, transcriptomics, metabolomics, and epigenomics to explore disease mechanisms, identify biomarkers, predict treatment responses, and personalize medical care. These trials employ high-throughput molecular data to guide patient selection, stratification, and therapy optimization, aiming to improve outcomes and minimize adverse effects through precision medicine approaches.

The primary types of omics-based clinical trials include genomics, proteomics, metabolomics, and transcriptomics. Genomics focuses on analyzing an organism's complete DNA sequence to understand gene structure, function, and their roles in health and disease. These trials progress through phases I to IV and commonly follow study designs such as interventional studies, observational studies, and expanded access studies. They are widely applied in areas like oncology, cardiovascular medicine, neurology, infectious diseases, and metabolic disorders, and serve various end users, including pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations (CROs), and hospitals and diagnostic laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The omics-based clinical trials market research report is one of a series of new reports from The Business Research Company that provides omics-based clinical trials market statistics, including the omics-based clinical trials industry's global market size, regional shares, competitors with the omics-based clinical trials market share, detailed omics-based clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the omics-based clinical trials market. This omics-based clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The omics-based clinical trials market size has grown strongly in recent years. It will grow from $29.10 billion in 2024 to $31.71 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to the increasing number of clinical trials utilizing omics technologies, a stronger focus on translational research, rising government funding and support, expanded availability of biobanks and biospecimens, and growing awareness of the advantages offered by precision therapies.

The omics-based clinical trials market size is expected to see strong growth in the next few years. It will grow to $44.08 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to the rising demand for personalized medicine, increasing adoption of multi-omics approaches, growing prevalence of chronic and rare diseases, expanding investment in genomic research and biotechnology, and heightened focus on biomarker discovery. Major trends in the forecast period include advancements in next-generation sequencing (NGS) technologies, integration of artificial intelligence with omics platforms, innovations in bioinformatics tools, progress in proteomics and metabolomics platforms, and enhanced integration of multi-omics data.

The growing demand for personalized medicine is expected to drive the expansion of the omics-based clinical trials market in the coming years. Personalized medicine involves tailoring disease prevention, diagnosis, and treatment to the unique characteristics of each patient. This demand is increasing due to advances in genomic technologies that enable faster, more cost-effective analysis of individual genetic profiles, guiding targeted therapies. Omics-based clinical trials support personalized medicine by identifying patients' genetic, proteomic, and metabolic profiles, allowing for more precise and effective treatment strategies. For example, in February 2023, the Personalized Medicine Coalition, a US-based professional membership organization, reported that 12 new personalized medicines were approved in 2022, accounting for roughly 34% of all newly approved therapies, marking a significant rise from previous years. Consequently, the growing adoption of personalized medicine is driving growth in the omics-based clinical trials market.

Companies in the omics-based clinical trials market are focusing on innovations such as HiFi sequencing technology to improve the accuracy, speed, and depth of multi-omics data analysis, thereby enhancing trial outcomes and personalized treatment strategies. HiFi sequencing is a next-generation sequencing (NGS) technology that produces long, highly accurate reads using circular consensus sequencing (CCS), enabling comprehensive analysis of genomes, transcriptomes, and epigenomes. For instance, in October 2024, Pacific Biosciences of California Inc., in collaboration with the Agency for Science, Technology, and Research (A\STAR) in Singapore and Macrogen Inc. in South Korea, launched a state-of-the-art genomics lab in Singapore. The facility employs advanced long-read sequencing technology to support applications such as whole genome sequencing, transcriptomics, epigenetics, and metagenomics. It also fosters collaboration between global researchers and local institutions, accelerating personalized medicine, rare disease diagnostics, and precision oncology, while providing training and shared access to high-throughput sequencing infrastructure in the Asia-Pacific region.

In June 2025, Bruker Corporation, a US-based manufacturer of scientific instruments and diagnostic tests, acquired Biocrates Life Sciences AG for an undisclosed amount. Through this acquisition, Bruker aims to strengthen its multiomics offerings by integrating Biocrates' mass spectrometry-based metabolomics technologies, delivering standardized, reproducible, and comprehensive workflows for life sciences and clinical research. Biocrates Life Sciences AG, based in Austria, specializes in providing omics-based clinical trial solutions.

Major players in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Societe Generale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, and BioAro Inc.

North America was the largest region in the omics-based clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in omics-based clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the omics-based clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The omics-based clinical trials market consists of revenues earned by entities by providing services such as genomics analysis, transcriptomics profiling, proteomics studies, and metabolomics assessments. The market value includes the value of related goods sold by the service provider or included within the service offering. The omics-based clinical trials market also includes sales of next-generation sequencing (NGS) platforms, mass spectrometry instruments, microarrays, bioinformatics software, reagents, and kits. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Omics-Based Clinical Trials Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on omics-based clinical trials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for omics-based clinical trials ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The omics-based clinical trials market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Genomics; Proteomics; Metabolomics; Transcriptomics
2) By Phase: Phase I; Phase II; Phase III; Phase IV
3) By Study Design: Interventional Studies; Observational Studies; Expanded Access Studies
4) By Application: Oncology; Cardiovascular; Neurology; Infectious Diseases; Metabolic Disorders
5) By End-User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Contract Research Organizations (CROs); Hospitals And Diagnostic Laboratories
Subsegments:
1) By Genomics: Whole Genome Sequencing; Whole Exome Sequencing; Targeted Gene Sequencing
2) By Proteomics: Protein Expression Profiling; Post-Translational Modifications Analysis; Protein-Protein Interaction Mapping
3) By Metabolomics: Targeted Metabolomics; Untargeted Metabolomics; Metabolic Flux Analysis
4) By Transcriptomics: Microarray Analysis; Single-Cell Transcriptomics; Gene Expression Profiling
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; GlaxoSmithKline Plc; Eli Lilly and Company; Novo Nordisk A/S; BioNTech SE; IQVIA Inc.; Laboratory Corporation of America Holdings; ICON Public Limited Company; SGS Societe Generale de Surveillance SA; Eurofins Scientific SE; Syneos Health Inc.; Illumina Inc.; Charles River Laboratories International Inc.; Parexel International Corporation; Bruker Corporation; Fulgent Genetics Inc.; Signios Biosciences; BioAro Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37840

1. Executive Summary

2. Omics-Based Clinical Trials Market Characteristics

3. Omics-Based Clinical Trials Market Trends And Strategies

4. Omics-Based Clinical Trials Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Omics-Based Clinical Trials Growth Analysis And Strategic Analysis Framework

5.1. Global Omics-Based Clinical Trials PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Omics-Based Clinical Trials Market Growth Rate Analysis
5.4. Global Omics-Based Clinical Trials Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Omics-Based Clinical Trials Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Omics-Based Clinical Trials Total Addressable Market (TAM)

6. Omics-Based Clinical Trials Market Segmentation

6.1. Global Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Genomics
Proteomics
Metabolomics
Transcriptomics
6.2. Global Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Phase I
Phase II
Phase III
Phase IV
6.3. Global Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interventional Studies
Observational Studies
Expanded Access Studies
6.4. Global Omics-Based Clinical Trials Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology
Cardiovascular
Neurology
Infectious Diseases
Metabolic Disorders
6.5. Global Omics-Based Clinical Trials Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceutical And Biotechnology Companies
Academic And Research Institutes
Contract Research Organizations (CROs)
Hospitals And Diagnostic Laboratories
6.6. Global Omics-Based Clinical Trials Market, Sub-Segmentation Of Genomics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Whole Genome Sequencing
Whole Exome Sequencing
Targeted Gene Sequencing
6.7. Global Omics-Based Clinical Trials Market, Sub-Segmentation Of Proteomics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Protein Expression Profiling
Post-Translational Modifications Analysis
Protein-Protein Interaction Mapping
6.8. Global Omics-Based Clinical Trials Market, Sub-Segmentation Of Metabolomics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Targeted Metabolomics
Untargeted Metabolomics
Metabolic Flux Analysis
6.9. Global Omics-Based Clinical Trials Market, Sub-Segmentation Of Transcriptomics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Microarray Analysis
Single-Cell Transcriptomics
Gene Expression Profiling

7. Omics-Based Clinical Trials Market Regional And Country Analysis

7.1. Global Omics-Based Clinical Trials Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Omics-Based Clinical Trials Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Omics-Based Clinical Trials Market

8.1. Asia-Pacific Omics-Based Clinical Trials Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Omics-Based Clinical Trials Market

9.1. China Omics-Based Clinical Trials Market Overview
9.2. China Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Omics-Based Clinical Trials Market

10.1. India Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Omics-Based Clinical Trials Market

11.1. Japan Omics-Based Clinical Trials Market Overview
11.2. Japan Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Omics-Based Clinical Trials Market

12.1. Australia Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Omics-Based Clinical Trials Market

13.1. Indonesia Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Omics-Based Clinical Trials Market

14.1. South Korea Omics-Based Clinical Trials Market Overview
14.2. South Korea Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Omics-Based Clinical Trials Market

15.1. Western Europe Omics-Based Clinical Trials Market Overview
15.2. Western Europe Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Omics-Based Clinical Trials Market

16.1. UK Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Omics-Based Clinical Trials Market

17.1. Germany Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Omics-Based Clinical Trials Market

18.1. France Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Omics-Based Clinical Trials Market

19.1. Italy Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Omics-Based Clinical Trials Market

20.1. Spain Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Omics-Based Clinical Trials Market

21.1. Eastern Europe Omics-Based Clinical Trials Market Overview
21.2. Eastern Europe Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Omics-Based Clinical Trials Market

22.1. Russia Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Omics-Based Clinical Trials Market

23.1. North America Omics-Based Clinical Trials Market Overview
23.2. North America Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Omics-Based Clinical Trials Market

24.1. USA Omics-Based Clinical Trials Market Overview
24.2. USA Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Omics-Based Clinical Trials Market

25.1. Canada Omics-Based Clinical Trials Market Overview
25.2. Canada Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Omics-Based Clinical Trials Market

26.1. South America Omics-Based Clinical Trials Market Overview
26.2. South America Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Omics-Based Clinical Trials Market

27.1. Brazil Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Omics-Based Clinical Trials Market

28.1. Middle East Omics-Based Clinical Trials Market Overview
28.2. Middle East Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Omics-Based Clinical Trials Market

29.1. Africa Omics-Based Clinical Trials Market Overview
29.2. Africa Omics-Based Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Omics-Based Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Omics-Based Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Omics-Based Clinical Trials Market Competitive Landscape And Company Profiles

30.1. Omics-Based Clinical Trials Market Competitive Landscape
30.2. Omics-Based Clinical Trials Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. GlaxoSmithKline Plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Omics-Based Clinical Trials Market Other Major And Innovative Companies

31.1. Novo Nordisk A/S
31.2. BioNTech SE
31.3. IQVIA Inc.
31.4. Laboratory Corporation of America Holdings
31.5. ICON Public Limited Company
31.6. SGS Societe Generale de Surveillance SA
31.7. Eurofins Scientific SE
31.8. Syneos Health Inc.
31.9. Illumina Inc.
31.10. Charles River Laboratories International Inc.
31.11. Parexel International Corporation
31.12. Bruker Corporation
31.13. Fulgent Genetics Inc.
31.14. Signios Biosciences
31.15. BioAro Inc.

32. Global Omics-Based Clinical Trials Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Omics-Based Clinical Trials Market

34. Recent Developments In The Omics-Based Clinical Trials Market

35. Omics-Based Clinical Trials Market High Potential Countries, Segments and Strategies

35.1 Omics-Based Clinical Trials Market In 2029 - Countries Offering Most New Opportunities
35.2 Omics-Based Clinical Trials Market In 2029 - Segments Offering Most New Opportunities
35.3 Omics-Based Clinical Trials Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer